-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

Benzinga·09/08/2026 15:22:30
Listen to the news
BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.